Co-Diagnostics, Inc. cash flow to debt ratio of -2.36K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Co-Diagnostics, Inc.'s free cash flow has increased -0.22% from $-29.90M last year to $-29.84M, signaling increasing performance

Co-Diagnostics, Inc.'s debt to equity ratio is 0.13, which means that the company's assets are healthy financed, signaling financial stability.

Co-Diagnostics, Inc.'s debt has increased relative to shareholder equity from 0.04 last year to 0.13 today, signaling weakened financials

Co-Diagnostics, Inc. has a net cash position, so leverage is healthy.

Co-Diagnostics, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Co-Diagnostics, Inc.'s profit margin has decreased (602.51%) in the last year from -961.37% to -6.75K%, signaling decreasing performance

Co-Diagnostics, Inc.'s short-term assets of $13.69M exceed its short-term liabilities of $3.54M

Co-Diagnostics, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Co-Diagnostics, Inc.'s return on equity of -164.92%, is lower than 15.00%, indicating bad performance

Co-Diagnostics, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Co-Diagnostics, Inc. had positive net income in only 1 out of 5 years, indicating unstable earnings

Co-Diagnostics, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Co-Diagnostics, Inc. has negative free cash flow, indicating cash burn

Co-Diagnostics, Inc.'s yearly earnings has decreased 24.59% since last year from $-37.64M to $-46.90M, signaling decreasing performance

Co-Diagnostics, Inc.'s yearly revenue has decreased 84.10% since last year from $3.92M to $622.49K, signaling decreasing performance

ROIC -170.99% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Co-Diagnostics, Inc.'s 3-year revenue CAGR of -73.70% is negative, indicating declining revenue over the past 3 years

Co-Diagnostics, Inc. had revenue growth in only 1 out of 5 years, indicating inconsistent revenue performance

Co-Diagnostics, Inc. had positive ROE in only 1 out of 5 years, indicating inconsistent returns on equity

Co-Diagnostics, Inc. has insufficient data to evaluate this check.

Co-Diagnostics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Co-Diagnostics, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Co-Diagnostics, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Co-Diagnostics, Inc. is overvalued relative to its fair value price of -19.70 based on Earnings Fair Value model

Co-Diagnostics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Co-Diagnostics, Inc. has a price-to-book ratio of 0.21x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Co-Diagnostics, Inc. has a price-to-sales ratio of 4.71x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue